BCM
MRSN

Bridgeway Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Bridgeway Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,020
Closed -$956K – 1297
2024
Q2 		$956K Buy
19,020
+9,728
+105% +$703K 0.02% 700
2024
Q1 		$1.04M Hold
9,292
– – 0.02% 737
2023
Q4 		$539K Sell
9,292
-13,976
-60% -$562K 0.01% 922
2023
Q3 		$739K Buy
+23,268
New +$1.11M 0.02% 789
2020
Q1 		– Sell
-6,376
Closed -$913K – 1332
2019
Q4 		$913K Buy
6,376
+1,864
+41% +$136K 0.01% 762
2019
Q3 		$178K Buy
4,512
+2,520
+127% +$183K ﹤0.01% 1199
2019
Q2 		$202K Hold
1,992
– – ﹤0.01% 1177
2019
Q1 		$262K Buy
+1,992
New +$251K ﹤0.01% 1178

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's MRSN Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2024, closing a stake of 19,020 shares — an estimated $956K sold.

Bridgeway Capital Management first reported a position in MRSN in Q1 2019 and held it in 8 quarters. The position peaked at $1.04M in Q1 2024. 113 funds tracked by Wall St. Rank hold MRSN as of Q3 2024.

  • Bridgeway Capital Management reported no remaining Mersana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 19,020 Mersana Therapeutics shares in Q3 2024, an estimated $956K.
  • Bridgeway Capital Management first reported a position in Mersana Therapeutics in Q1 2019 and held it in 8 quarters.
  • Bridgeway Capital Management's Mersana Therapeutics position peaked at $1.04M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.